In TME, ALKBH5 overexpression can inhibit pancreatic cancer by decreasing the level of m6A RNA modification of WIF-1, blocking the activation of Wnt signaling, and increasing the sensitivity of pancreatic cancer cells to drugs (Tang et al., 2020). Here, ALKBH5 is linked to familial pancreatic carcinoma.